CHMP backs Novo Nordisk's denecimig and Sogroya as CagriSema posts 21% weight loss
The EMA committee recommended FREHEMGO for hemophilia A and once-weekly somapacitan for children with idiopathic short stature, pending European Commission sign-off.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 28 03:10 ETSource: AD HOC NEWS
The wire
- 01Novo Nordisk received two positive CHMP opinions and reported CagriSema cut weight 12.4% on average in diabetes patients and 21% versus placebo in obesity at the 1.0 mg dose.
- 02Sogroya's somapacitan extension and the CagriSema data bear directly on peptide prescribing in growth disorders and obesity, where tirzepatide is the comparator.
- 03European Commission approval is still required for Sogroya; first-country launch of FREHEMGO is expected in Q4 2026, with broader EU rollout in early 2027.
From the source
Read at ad-hoc-news.deNovo Nordisk Wins European Backing for Two Specialty Drugs as CagriSema Outperforms Eli Lilly Rival
Novo Nordisk has secured a pair of favorable regulatory opinions in Europe while simultaneously posting late-stage data that strengthens its hand against Eli Lilly in the race for the metabolic-therapy market. The twin developments, alongside a widening artificial-intelligence partnership and a fresh philanthropic commitment, sketch a company working to diversify well beyond its flagship diabetes
